Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Itamar Raz's publication output changed over time?
ScholarIQpublication output · 1990–2022
Output grew0% over the shown period — from 1 works in 1990 to 1 in 2022.
1
1
2
1
1
1
1
2
1
1
1990200120062013201420152018201920202022
What are the most-cited papers on Itamar Raz?
ScholarIQmost cited works
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke, Tomás Berl, Marc A. Pohl, Julia B. Lewis, Eberhard Ritz, Robert C. Atkins, Richard Rohde, Itamar Raz
New England Journal of Medicine. 20016,021 CitationsOPEN ACCESS
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Philippe Gabríel Steg, Jaime A. Davidson, Boaz Hirshberg, Peter Öhman, Robert Frederich, Stephen D. Wiviott, Elaine Hoffman, Matthew A. Cavender, Jacob A. Udell, Nihar R. Desai, Ofri Mosenzon, Darren K. McGuire, Kausik K. Ray, Lawrence A. Leiter, Itamar Raz
New England Journal of Medicine. 20133,486 CitationsOPEN ACCESS
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker, Stephen D. Wiviott, Itamar Raz, KyungAh Im, Erica L. Goodrich, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Remo H.M. Furtado, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Marc S. Sabatine
The Lancet. 20182,848 Citations
Type 2 diabetes mellitus
Ralph A. DeFronzo, Ele Ferrannini, Leif Groop, Robert R. Henry, William H. Herman, Jens J. Holst, Frank B. Hu, C. Ronald Kahn, Itamar Raz, Gerald I. Shulman, Donald C. Simonson, Marcia A. Testa, Ram Weiss
Nature Reviews Disease Primers. 20152,590 Citations
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors Task Force Members, L Rydén, Eberhard Standl, M. Bartnik, Greet Van den Berghe, John Betteridge, Menko‐Jan de Boer, Francesco Cosentino, Bengt Jönsson, Markku Laakso, K. Malmberg, Silvia G. Priori, Jan Östergren, J Tuomilehto, Inga S. Þráinsdóttir, Other Contributors, Ilse Vanhorebeek, Marco Stramba‐Badiale, Peter Lindgren, Qing Qiao, Silvia G. Priori, J J Blanc, Andrzej Budaj, A. John Camm, V. Dean, Jaap W. Deckers, Kenneth Dickstein, J. Lekakis, Keith McGregor, Marco Metra, João Morais, A. Osterspey, Juan Tamargo, José Luís Zamorano, Document Reviewers, Jaap W. Deckers, M Bertrand, B Charbonnel, Erland Erdmann, Ele Ferrannini, Allan Flyvbjerg, H. Gohlke, J.R.G. Juanatey, Ian Graham, Pedro Monteiro, Klaus G. Parhofer, Kalevi Pyörälà, Itamar Raz, Guntram Schernthaner, Massimo Volpe, David M. Wood
European Heart Journal. 20061,652 CitationsOPEN ACCESS
Related on ScholarIQ
Hebrew University of Jerusalem
Institution
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
Paper
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Paper
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Paper
Type 2 diabetes mellitus
Paper
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Paper